Osborne Clarke has successfully advised iOnctura B.V., a clinical-stage biopharmaceutical company focused on addressing neglected and hard-to-treat cancers, in securing EUR 80 million during its Series B financing round. The funding was spearheaded by Syncona Limited, with additional contributions from the European Innovation Council’s EIC Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. This transaction marks another collaboration between Osborne Clarke and iOnctura, following a previous engagement during the company’s Series A round. The legal team from Osborne Clarke included Partner Herke van Hulst, Senior Associate Wouter Kok, and Associate Angela Saldanha, along with involvement from other specialized members of their firm.

Biopharmaceuticals, Venture Capital, Legal Services,Europe